StoryOther
Alphabet launches Isomorphic Labs, a DeepMind spinout for AI drug discovery led by Demis Hassabis
Demis Hassabis announced Isomorphic Labs as a new Alphabet company that will reimagine drug discovery with an AI-first approach, building on DeepMind's AlphaFold 2 work. Hassabis leads it as CEO while remaining DeepMind CEO to facilitate collaboration between the organizations.
- Isomorphic treats biology as an information processing system, applying advanced AI to create predictive and generative models of biological phenomena.
- The team combines expertise in AI, chemistry, biophysics, and engineering under a 'digital biology' mandate.
- Isomorphic aims to understand fundamental mechanisms of life to develop cures for serious diseases.